Assistant Professor — Non-Viral Immune-Cell Therapies

Ohio State University; Columbus (OH); On-site; USD 110,000 - 170,000; Full time

Job summary

The Ohio State University in Columbus, OH invites applications for a tenure-track Assistant Professor position in the Department of Biomedical Engineering. The focus is on non-virally engineered immune cell therapies for regenerative medicine and tissue restoration; start as early as Fall 2027.

The successful candidate will establish an independent funded research program, mentor students, teach undergraduate and graduate courses, and collaborate across disciplines with physicians and scientists

Qualifications

• Ph.D., M.D., Pharm.D., or equivalent degree in Biomedical Engineering, Pharmaceutical Sciences, or related fields.
• Demonstrated research expertise in non-viral engineering of immune cells and their development or application as cell therapies.
• A research record and/or proposed program addressing regenerative medicine, tissue repair, restoration of tissue or organ function, or related mechanisms.
• Commitment to teaching, mentorship, and excellence in academia.
• Ability to collaborate effectively in an academic setting.
• Evidence or potential for sustained extramural funding.

Responsibilities

• Establish and lead an independent research program.
• Mentor undergraduate, graduate, and postdoctoral trainees.
• Teach undergraduate and graduate courses in engineering.
• Collaborate across disciplines with physician-scientists to advance therapies.
• Contribute to department, college, and university service.

Skills

Non-viral engineering

Regenerative medicine research

Teaching and mentorship

Leadership and collaboration

Education

PhD, MD, PharmD or equivalent in Biomedical Engineering or related fields

Tools

Microphysiological systems

Organ-on-chip

Tissue engineering

Job description

The Ohio State University in Columbus, OH invites applications for a tenure-track Assistant Professor position in the Department of Biomedical Engineering. The focus is on non-virally engineered immune cell therapies for regenerative medicine and tissue restoration; start as early as Fall 2027.

The successful candidate will establish an independent funded research program, mentor students, teach undergraduate and graduate courses, and collaborate across disciplines with physicians and scientists